11:30am Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation
Time: 11:30 am
day: Day One Discovery Track
Details:
- LCB’s site-specific ConjuAllTM platform enables discrete DAR ADCs with circulation stable bioconjugation
- LCB’s proprietary betaglucuronidase technology enables unprecedented preclinical therapeutic indexes through tumor selective release and activation of payload
- Early clinical safety and efficacy across payload classes validate the LCB platform
